CYP2C19 and major depressive disorder: These dissimilarities among the selected studies demonstrate inconsistencies regarding the CYP2C19 gene polymorphisms’ association with MDD clinical characteristics and certain drug metabolizations, making it essential for studies to analyze confounding factors to confirm associations in varying contexts.